Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Amsterdam played host to this year's edition of the International Conference on Advanced Technologies & Treatments for ...

Which company has replaced IBM as the largest employer in Research Triangle Park? And who are the top hirers in Wake, Durham, Orange, Johnston and Chatham?

Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...

is $3.27 Novo Nordisk A/S has a trailing 12 month Price to Earnings (P/E) ratio of 24.0 while the S&P 500 average is 29.3 Its forward earnings per share (EPS) is $4.07 and its forward P/E ratio is ...

US-based Lilly and Danish Novo Nordisk have seen skyrocketing global demand for their innovative weight-loss drugs, with ...

The new class of weight-loss medicines that has taken the world by a storm will now become available in India, with the ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

The plant will make three types of insulin, which Civica has pledged to sell for $30 a vial and $55 for a box of five pens.

Wegovy is a prescription medication designed for chronic weight management, offering hope to individuals struggling with ...

NEW YORK, NY / ACCESS Newswire / March 15, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE ... The firm has been ranked in the ...